Voronoi Inc (310210)

Currency in KRW
181,000
-28,500(-13.60%)
Closed·
310210 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
175,100195,600
52 wk Range
91,000375,500
Key Statistics
Bid/Ask
180,900.00 / 181,000.00
Prev. Close
209,500
Open
192,800
Day's Range
175,100-195,600
52 wk Range
91,000-375,500
Volume
215.66K
Average Volume (3m)
108.5K
1-Year Change
76.7578%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
310210 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
350,000
Upside
+93.37%
Members' Sentiments
Bearish
Bullish
ProTips
Stock has taken a big hit over the last week

Voronoi Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

3 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 350,000
(+93.37% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Earnings

Latest Release
Mar 20, 2026
EPS / Forecast
-239.27 / --
Revenue / Forecast
22.06M / --
EPS Revisions
Last 90 days

310210 Income Statement

Compare 310210 to Peers and Sector

Metrics to compare
310210
Peers
Sector
Relationship
P/E Ratio
−74.5x−22.4x−0.5x
PEG Ratio
3.16−0.880.00
Price/Book
41.1x3.4x2.6x
Price / LTM Sales
501.9x33.2x3.0x
Upside (Analyst Target)
43.2%90.3%58.6%
Fair Value Upside
Unlock11.3%10.2%Unlock

Voronoi, Inc. researches, develops, and discovers small molecule kinase inhibitors in South Korea. Its products pipeline includes VRN01, an oral leucine rich repeat kinase 2 inhibitor targeting glioblastoma multiforme to treat brain and pancreatic cancers; VRN07, VRN06, and VRN11 for the treatment of lung cancer; VRN08 and VRN10 to treat breast cancer; and VRN02 for the treatment of rheumatoid arthritis and atopic dermatitis. The company’s products pipeline also comprise VRN04-1 to treat autoimmune diseases; VRN04-2 for the treatment of multiple sclerosis and amyotrophic lateral sclerosis; VRN13 to treat pulmonary arterial hypertension; and VRN14 for the treatment of refractory solid cancer. Voronoi, Inc. was incorporated in 2015 and is based in Incheon, South Korea.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
732.83K4.07%153.53B
Other Institutional Investors
0.000.00%0.00
Public Companies & Retail Investors
17.27M95.93%3.62T
Total
18M100.00%3.77T

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Vanguard Capital Management, LLC1.79%322,25967,513,261
BlackRock, Inc.1.15%207,13343,394,364

People Also Watch

208,000
010120
-8.37%
88,600
298380
-11.22%
639,000
005380
-8.71%
116,500
141080
-14.40%
889,000
267260
-7.01%

FAQ

What Is the Voronoi (310210) Stock Price Today?

The Voronoi stock price today is 181,000 KRW.

What Stock Exchange Does Voronoi Trade On?

Voronoi is listed and trades on the KOSDAQ.

What Is the Stock Symbol for Voronoi?

The stock symbol for Voronoi is "310210."

What Is the Voronoi Market Cap?

As of today, Voronoi market cap is 3.77T KRW.

What Is Voronoi's Earnings Per Share (TTM)?

The Voronoi EPS (TTM) is -2,800.

From a Technical Analysis Perspective, Is 310210 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Voronoi Stock Split?

Voronoi has split 1 times.

How Many Employees Does Voronoi Have?

Voronoi has 140 employees.

What is the current trading status of Voronoi (310210)?

As of Jun 08, 2026, Voronoi (310210) is trading at a price of 181,000 KRW, with a previous close of 209,500 KRW. The stock has fluctuated within a day range of 175,100 KRW to 195,600 KRW, while its 52-week range spans from 91,000 KRW to 375,500 KRW.

What Is Voronoi (310210) Price Target According to Analysts?

The average 12-month price target for Voronoi is 350,000 KRW, with a high estimate of 450000 KRW and a low estimate of 300000 KRW. 3 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +93.37% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2026 - Fusion Media Limited. All Rights Reserved.